Online inquiry

IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15019MR)

This product GTTS-WQ15019MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CSF1R gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001288705.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1436
UniProt ID P07333
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ15019MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4050MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BI 655130
GTTS-WQ15794MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ10544MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY-3015014
GTTS-WQ8198MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA hLIV22
GTTS-WQ6413MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CT-011
GTTS-WQ6451MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CT-P23
GTTS-WQ518MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 4D11
GTTS-WQ11197MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-1873
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW